UAE Femtech Startup Secures $1.2M Funding for Fertility & Hormonal Health Innovation

• A pre-seed amount of $1.2 million has been raised by a UAE-headquartered femtech startup focused on fertility and hormonal health
• The round was headed by early-stage VC firm, Annex Investments, and New York-based 25 Madison
• The funds will likely be used to fund the startup's mission to revolutionize women's health solutions, and particularly in the fertility and hormonal wellness space

Femtech startup Ovasave, based in the UAE and specialising in fertility and hormonal health, has raised US$1.2 million in a pre-seed funding round. The round was supported by a combination of regional and international investors, with an early-stage VC investor, Annex Investments (a UAE-based hybrid venture single-family office), and New York-headquartered 25 Madison leading the pack. Other backers included strategic angel investors and top family offices in the UAE and Saudi Arabia.

The company provides a full-service platform consisting of in-home hormone testing, remote consultations, personalized supplement regimens, and facilitated access to top fertility clinics for services such as egg freezing. Ovasave also has an expanding corporate benefits program, assisting employers in offering reproductive health as part of their overall workplace wellness initiatives.

In an interview with Inc. Arabia, co-founders Mahloul and Abu Zant explained that Ovasave was born out of a need to bridge significant gaps in women’s reproductive care in the region.

“People track their steps, calories, and sleep—but not hormones,” said CEO Mahloul. “Hormonal health is still often ignored unless a doctor mentions it. We’re changing that by making hormone testing simple, accessible, and empowering.”

She also spoke on how age-old assumptions regarding fertility benefits still limit access.

“Fertility care is often treated as a luxury for the few, when it should be viewed as a mainstream healthcare need,” Mahloul emphasized. “With the right model, fertility support can be proactive, preventive, and affordable. That’s exactly what we’re delivering. Ovasave connects consumers, providers, and payers, making hormonal and fertility care more accessible and relevant to women’s daily lives.”

Beyond just patient support, Ovasave’s mission is to transform women’s healthcare from reactive to proactive. Rather than waiting until a problem arises, the platform enables earlier screening, continuous monitoring, and structured care—aimed at improving outcomes and reducing systemic healthcare burdens.

“The healthcare system usually focuses on treatment after something goes wrong,” Mahloul noted. “We’re prioritizing education, early screening, and preventive care to truly improve health outcomes.”

Abu Zant further noted that femtech will play a crucial role in spearheading this healthcare change, and specifically by interoperating with legacy systems.

"Much of the patient experience still occurs offline. But technologies such as home-based testing, digital triage, and AI-driven protocols have the ability to reframe care from episodic to continuous," he said. Femtech is uniquely placed to fill that gap.

He further emphasized the significance of cultural transformation in underpinning this change—pointing to the fact that while taboos are shattered and awareness grows, femtech sites such as Ovasave will be at the forefront of enabling women to assume control of their own health with confidence and clarity.